134 related articles for article (PubMed ID: 11420727)
1. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias?
Minucci S; Nervi C; Lo Coco F; Pelicci PG
Oncogene; 2001 May; 20(24):3110-5. PubMed ID: 11420727
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia.
Ferrara FF; Fazi F; Bianchini A; Padula F; Gelmetti V; Minucci S; Mancini M; Pelicci PG; Lo Coco F; Nervi C
Cancer Res; 2001 Jan; 61(1):2-7. PubMed ID: 11196162
[TBL] [Abstract][Full Text] [Related]
3. Targeting aberrant transcriptional repression in acute myeloid leukemia.
Moe-Behrens GH; Pandolfi PP
Rev Clin Exp Hematol; 2003 Jun; 7(2):139-59. PubMed ID: 14763160
[TBL] [Abstract][Full Text] [Related]
4. Retinoic acid targets DNA-methyltransferases and histone deacetylases during APL blast differentiation in vitro and in vivo.
Fazi F; Travaglini L; Carotti D; Palitti F; Diverio D; Alcalay M; McNamara S; Miller WH; Lo Coco F; Pelicci PG; Nervi C
Oncogene; 2005 Mar; 24(11):1820-30. PubMed ID: 15688037
[TBL] [Abstract][Full Text] [Related]
5. [Acute promyelocytic leukemia, histone deacetylase, and response to retinoids].
Jeanteur P
Bull Cancer; 1998 Apr; 85(4):301-3. PubMed ID: 9752292
[TBL] [Abstract][Full Text] [Related]
6. Retinoic acid receptors, hematopoiesis and leukemogenesis.
Collins SJ
Curr Opin Hematol; 2008 Jul; 15(4):346-51. PubMed ID: 18536573
[TBL] [Abstract][Full Text] [Related]
7. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.
Fliegauf M; Stock M; Berg T; Lübbert M
Oncogene; 2004 Dec; 23(56):9070-81. PubMed ID: 15489901
[TBL] [Abstract][Full Text] [Related]
8. Molecular signature of retinoic acid treatment in acute promyelocytic leukemia.
Meani N; Minardi S; Licciulli S; Gelmetti V; Coco FL; Nervi C; Pelicci PG; Müller H; Alcalay M
Oncogene; 2005 May; 24(20):3358-68. PubMed ID: 15735696
[TBL] [Abstract][Full Text] [Related]
9. Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation.
Minucci S; Maccarana M; Cioce M; De Luca P; Gelmetti V; Segalla S; Di Croce L; Giavara S; Matteucci C; Gobbi A; Bianchini A; Colombo E; Schiavoni I; Badaracco G; Hu X; Lazar MA; Landsberger N; Nervi C; Pelicci PG
Mol Cell; 2000 May; 5(5):811-20. PubMed ID: 10882117
[TBL] [Abstract][Full Text] [Related]
10. Effects of histone deacetylase inhibitors, sodium phenyl butyrate and vitamin B3, in combination with retinoic acid on granulocytic differentiation of human promyelocytic leukemia HL-60 cells.
Merzvinskyte R; Treigyte G; Savickiene J; Magnusson KE; Navakauskiene R
Ann N Y Acad Sci; 2006 Dec; 1091():356-67. PubMed ID: 17341628
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway.
Insinga A; Monestiroli S; Ronzoni S; Gelmetti V; Marchesi F; Viale A; Altucci L; Nervi C; Minucci S; Pelicci PG
Nat Med; 2005 Jan; 11(1):71-6. PubMed ID: 15619634
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins.
Moldenhauer A; Frank RC; Pinilla-Ibarz J; Holland G; Boccuni P; Scheinberg DA; Salama A; Seeger K; Moore MA; Nimer SD
J Leukoc Biol; 2004 Sep; 76(3):623-33. PubMed ID: 15197237
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia.
He LZ; Tolentino T; Grayson P; Zhong S; Warrell RP; Rifkind RA; Marks PA; Richon VM; Pandolfi PP
J Clin Invest; 2001 Nov; 108(9):1321-30. PubMed ID: 11696577
[TBL] [Abstract][Full Text] [Related]
14. Response of retinoic acid-resistant KG1 cells to combination of retinoic acid with diverse histone deacetylase inhibitors.
Savickiene J; Treigyte G; Magnusson KE; Navakauskiene R
Ann N Y Acad Sci; 2009 Aug; 1171():321-33. PubMed ID: 19723072
[TBL] [Abstract][Full Text] [Related]
15. Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation.
Nasr R; Guillemin MC; Ferhi O; Soilihi H; Peres L; Berthier C; Rousselot P; Robledo-Sarmiento M; Lallemand-Breitenbach V; Gourmel B; Vitoux D; Pandolfi PP; Rochette-Egly C; Zhu J; de Thé H
Nat Med; 2008 Dec; 14(12):1333-42. PubMed ID: 19029980
[TBL] [Abstract][Full Text] [Related]
16. Pro-proliferative function of the long isoform of PML-RARalpha involved in acute promyelocytic leukemia.
Tussié-Luna MI; Rozo L; Roy AL
Oncogene; 2006 Jun; 25(24):3375-86. PubMed ID: 16434964
[TBL] [Abstract][Full Text] [Related]
17. Role of histone deacetylases in acute leukemia.
Fenrick R; Hiebert SW
J Cell Biochem Suppl; 1998; 30-31():194-202. PubMed ID: 9893271
[TBL] [Abstract][Full Text] [Related]
18. Gfi-1 attaches to the nuclear matrix, associates with ETO (MTG8) and histone deacetylase proteins, and represses transcription using a TSA-sensitive mechanism.
McGhee L; Bryan J; Elliott L; Grimes HL; Kazanjian A; Davis JN; Meyers S
J Cell Biochem; 2003 Aug; 89(5):1005-18. PubMed ID: 12874834
[TBL] [Abstract][Full Text] [Related]
19. The integrity of the charged pocket in the BTB/POZ domain is essential for the phenotype induced by the leukemia-associated t(11;17) fusion protein PLZF/RARalpha.
Puccetti E; Zheng X; Brambilla D; Seshire A; Beissert T; Boehrer S; Nürnberger H; Hoelzer D; Ottmann OG; Nervi C; Ruthardt M
Cancer Res; 2005 Jul; 65(14):6080-8. PubMed ID: 16024608
[TBL] [Abstract][Full Text] [Related]
20. Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases.
Göttlicher M
Ann Hematol; 2004; 83 Suppl 1():S91-2. PubMed ID: 15124690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
